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Temporospacial overexpression or inactivation of genes in
mouse models has undeniably boosted biomedical research.
This is most commonly achieved using the Cre-loxP tech-
nique, where mice expressing Cre recombinase driven by
a tissue-specific or inducible promoter are bred with mice in
which one or more exons of a gene of interest are flanked by
LoxP sites (1). This allows for a more in-depth view of the
gene function in the context of a particular time frame and
tissue system, while avoiding unwanted effects due to the
absence of this gene during development.
However, in the recent years several pitfalls have
emerged related to this technique (2–4). There have been
reports of disturbed endogenous gene expression at the
site of the Cre-transgene insertion (4), low or mosaic Cre
expression (5,6), and expression in undesired tissues, such
as unwanted Cre activity in nutrient-sensing neurons from
transgenic mice that express Cre under the control of Ins2
and Pdx1 promoters (7,8). Equally disturbing is the finding
that high Cre activity can cause chromosomal rearrange-
ments, apoptosis, and decreased proliferation (9–11). Par-
ticularly for diabetes and central nervous system research,
these caveats have been reviewed in detail (2,3).
In this issue of Diabetes, Oropeza et al. (12) de-
scribe yet another concern in the tamoxifen-inducible
MIP-CreERT1Lphi mouse line caused by transgenic hu-
man growth hormone (hGH) expression. In the 1980s,
a pioneering study described that the presence of introns
induces more efficient transgene expression (13). Soon
after, this principle was demonstrated using heterologous
introns in animals (14). In the early 1990s, the entire
hGH gene was inserted downstream of the Cre fragment
as a transgene enhancer (15) and has become a routine
strategy ever since. Recently, however, it has been shown
that this can result in a bicistronic Cre-hGH mRNA. As
a result, the mRNA is translated not only in Cre recom-
binase but also in functional hGH (16,17). Interestingly,
hGH can activate both the growth hormone receptor
and the prolactin receptor (PRLR) (17,18). Particularly
on b-cells, hGH acts as a lactogen and binds to the
PRLR present on b-cells, hereby inducing pregnancy-related
changes, such as an increase in b-cell mass and insulin con-
tent, induction of serotonin synthesis, and protection
against the b-cell toxin streptozotocin (STZ). Next to a preg-
nancy phenotype, impaired glucose-stimulated insulin secre-
tion and decreased b-cell GLUT2 levels were observed.
The MIP-CreERT1Lphi mouse line was welcomed in the
field as it was the first that used an 8.5-kb fragment of the
mouse Ins1 promoter, driving Cre activity exclusively to
b-cells while being absent in the brain (7). In addition, no
adverse effects on glucose tolerance and glucose-stimulated
Ca2+ release were observed (19). However, Oropeza et al.
(12) provide a more extensive and detailed analysis of
this mouse model. First, strong evidence is provided using
higher resolution techniques and the mT/mG reporter line
(20) that Cre activity is indeed exclusively found in b-cells
and not in hypothalamic or hindbrain nuclei, as was report-
ed before in other strains (7,8). Furthermore, whole-body
glucose homeostasis was similar to controls, both on nor-
mal chow and after a high-fat, high-sucrose (HFHS) diet.
However, they observed that despite secreting normal
amounts of insulin upon in vitro glucose stimulation there
was an increase in pancreatic islet number and insulin
content. Strikingly, MIP-CreERT animals on both C57BL/6
and FVB backgrounds were strongly protected against the
type 2 diabetes–inducing HFHS/STZ regimen. Significant
resistance was also seen for single high-dose STZ adminis-
tration. Similar to the previously reported strains (17),
MIP-CreERT mice express high levels of hGH in islets, in-
dependent of tamoxifen administration. After autocrine/
paracrine activation of the PRLR, this results in Tryptophan
hydroxylase-1 (Tph1) and -2 (Tph2) expression, which in
turn induces serotonin biosynthesis. Finally, the authors
provide evidence that serotonin negatively affects compen-
satory a-cell proliferation and glucagon secretion upon
HFHS/STZ in this mouse line (Fig. 1).
Interestingly, Oropeza et al. (12) did not observe
impaired glucose-stimulated insulin secretion and decreased
GLUT2 levels as was shown before in the Pdx1-CreLate
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model that also expresses hGH in islets (17). This suggests
that these impairments are independent of hGH bioactiv-
ity. Another explanation could be a gene-dose response of
hGH in different lines, as the levels of hGH protein could
depend on the promoter type, insertion site, and the
mouse strain, as suggested previously (21). Adding quan-
tification of absolute islet hGH levels by ELISA or high-
performance liquid chromatography would allow a direct
comparison of hGH levels between mouse strains. Next to
islets, lower hGH mRNA levels were also detected in the
arcuate nucleus and ventromedial hypothalamus, but the
question remains as to whether this has considerable effects
on physiology. For example, whole-genome expression pro-
filing on these microdissected hypothalamic regions could
possibly address this issue. Finally, this study is the first
to demonstrate additional transgene-related effects on pan-
creatic a-cells. Whether this phenomenon also occurs in
other pancreatic driver lines expressing hGH could be
the subject of future research.
Reports such as this are crucial to help move the
field forward. The hGH minigene has been used as
a transgene enhancer since the beginning of conditional
mouse targeting, extending into various research areas,
with a total number of lines exceeding well over 200
(G. de Faudeur, B. Ramos-Molina, B.B., F. Schuit, J.W.M.C.,
unpublished data). In several lines, bioactive hGH has
now been demonstrated in islets, the pituitary, and the
hypothalamus. On the other hand, no hGH protein was
found in the liver, despite high levels of Cre-hGH mRNA
(16). The reason for this tissue-dependent translation is
unknown. Validating each line in great detail, such as the
MIP-CreERT line, is therefore key to the design of future
experiments as well as for the careful reinterpretation of
published work.
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Figure 1—MIP-CreERTmice express high levels of bioactive hGH in pancreatic b-cells. This activates the prolactin receptor, which induces
serotonin biosynthesis and causes protection against HFHS/STZ. b-Cell serotonin has a paracrine effect on pancreatic a-cells, negatively
influencing a-cell number and glucagon secretion (12).
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